Deal typePrivate Equity & Transaction Services
IndustryLife Sciences
Client nameCNX Therapeutics
CNX Therapeutics, a speciality pharmaceutical company focused on improving patient access to essential medicines, has acquired the global Sativex® (nabiximols) business from Jazz Pharmaceuticals plc
Sativex® is indicated for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not adequately responded to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.
BDO provided financial due diligence to CNX on the acquisition.
Sativex® is indicated for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not adequately responded to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.
BDO provided financial due diligence to CNX on the acquisition.
"It was a pleasure to once again support CNX Therapeutics on their latest acquisition of Sativex® from Jazz Pharmaceuticals. This continues to enhance their CNX portfolio."
Lewis Winston, Director, BDO LLP
The BDO project team included:
Andrew Howson, Lewis Winston, Amy Banister, Sophie Lamb (Financial due diligence)